CLINICAL TRIALS PROFILE FOR ALLOPURINOL; LESINURAD
✉ Email this page to a colleague
All Clinical Trials for allopurinol; lesinurad
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01493531 ↗ | Combining Lesinurad With Allopurinol in Inadequate Responders | Completed | Ardea Biosciences, Inc. | Phase 3 | 2011-12-01 | This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol. |
| NCT01508702 ↗ | Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors | Completed | Ardea Biosciences, Inc. | Phase 3 | 2012-01-01 | This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat. |
| NCT01510158 ↗ | Combining Lesinurad With Allopurinol in Inadequate Responders | Completed | Ardea Biosciences, Inc. | Phase 3 | 2012-01-01 | This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol. |
| NCT01808131 ↗ | Lesinurad and Allopurinol Combination Extension Study in Gout | Completed | Ardea Biosciences, Inc. | Phase 3 | 2013-02-01 | This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with allopurinol over a long-term timeframe. |
| NCT02581553 ↗ | Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability | Completed | Ardea Biosciences, Inc. | Phase 1 | 2015-10-01 | This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food. |
| NCT02888054 ↗ | Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence | Completed | Ardea Biosciences, Inc. | Phase 1 | 2016-08-30 | This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects |
| NCT03272425 ↗ | Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. | Completed | Ardea Biosciences, Inc. | Phase 1 | 2017-08-14 | To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in healthy adult subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for allopurinol; lesinurad
Condition Name
Clinical Trial Locations for allopurinol; lesinurad
Trials by Country
Clinical Trial Progress for allopurinol; lesinurad
Clinical Trial Phase
Clinical Trial Sponsors for allopurinol; lesinurad
Sponsor Name
